We are recruiting a technical assistant to join our work on dissecting the genetic and epigenetic basis of cancer and immune diseases using next generation sequencing. Our lab is based at the CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences in Vienna, on the campus of one of the world’s largest hospitals and medical schools, pursuing an ambitious research program in molecular medicine.
At CeMM, we take career development of our staff seriously. For example, we will train the successful candidate in state-of-the-art technologies that are in high demand in academia and industry, and we encourage contribution to and co-authorship of scientific publications. Importantly, genomic medicine is a hot topic in Austria and internationally, creating a highly promising area for a career in biomedical research and applications.
- Bachelor or Master degree (or equivalent) with strong wet-lab experience
- High accuracy, reliability, precision under time pressure, and organizational skills
- High motivation and commitment, proactive mindset, getting-things-done attitude
- Prior experience working with DNA and/or RNA assays is mandatory. Experience with next generation sequencing is a plus
- Friendly, collaborative mindset and ability to work well in an international environment
- Written and oral communication skills in English (German skills are not required)
- Motivation to work in one of the fastest-moving and most future-oriented areas of biomedicine
- Library preparation for next generation sequencing (manually and with automated systems)
- Next generation sequencing on Illumina machines (NovaSeq, HiSeq 3000/4000, NextSeq, Miseq, etc.)
- Optimization and testing of new protocols, e.g. for CRISPR screens, single-cell sequencing, and epigenome editing
- Troubleshooting of technical problems in the sample preparation and sequencing workflows
- Contribution to lab management, training of new lab members, and scientific publications
The Lab (http://epigenomics.cemm.oeaw.ac.at/)
The Medical Epigenomics Lab at CeMM pursues an interdisciplinary and highly collaborative research program aimed at understanding the cancer epigenome and establishing its utility for precision medicine. The lab is internationally well connected and active in several fields:
- Epigenomics. Many diseases show widespread deregulation of epigenetic cell states. As members of the International Human Epigenome Consortium, we use epigenome sequencing to dissect the epigenetic basis of cancer and immune disorders.
- Technology. Groundbreaking biomedical research is often driven by new technologies. Our lab is therefore heavily invested into technology development, including single-cell sequencing, CRISPR screens, and epigenome editing.
- Bioinformatics. New algorithms and advanced computational methods allow us to infer epigenetic cell states from large datasets, in order to reconstruct the epigenetic landscape of cellular differentiation and complex diseases.
- Diagnostics. New technologies (genome sequencing, mobile devices, etc.) provide important information for personalized medicine. We develop and validate assays and algorithms for translating the value of digital medicine into routine clinical practice.
Our lab is co-located with and maintains tight links to the Biomedical Sequencing Facility (BSF). The BSF is Austria’s first and leading center of expertise for next generation sequencing in biomedicine, jointly operated by the Medical University of Vienna and CeMM.
The Principal Investigator (http://cemm.at/research/groups/christoph-bock-group/)
Christoph Bock is a principal investigator at CeMM, a guest professor at the Medical University of Vienna, and the scientific coordinator of the Biomedical Sequencing Facility (BSF). He obtained his PhD at the Max Planck Institute for Informatics in 2008, followed by three years of postdoctoral research at the Broad Institute of MIT and Harvard, where he contributed to the NIH Roadmap Epigenomics project. He has been a principal investigator in BLUEPRINT (International Human Epigenome Consortium), and he co-founded Genom Austria, a citizen science project on the role of genomics in society. He has received several research awards, including the Max Planck Society’s Otto Hahn Medal (2009), an ERC Starting Grant (2016-2021), and the Overton Prize of the International Society of Computational Biology (2017).
The Institute (http://www.cemm.at/)
CeMM is an international research institute of the Austrian Academy of Sciences and a founding member of EU-LIFE. It has an
outstanding track record of top-notch science (last five years: >10 papers in Nature/Cell/Science/NEJM, >25 papers in Nature/Cell sister journals) and medical translation. With just over a hundred researchers, CeMM provides a truly collaborative and personal environment, while maintaining critical mass and all relevant technologies. Research at CeMM focuses on cancer, inflammation, and immune disorders. CeMM is located at the center of one of the largest medical campuses in Europe, within walking distance of Vienna’s historical city center. A study by “The Scientist” placed CeMM among the top-5 best places to work in academia world-wide (http://the-scientist.com/2012/08/01/best-places-to-work-academia-2012). Vienna is frequently ranked the world’s best city to live. It is a United Nations city with a large English-speaking community. The official language at CeMM is English, and more than 40 different nationalities are represented at the institute.
Please apply online (https://cemm.jobbase.io/job/132eh0y2) with cover letter, CV, academic transcripts, and contact details of three referees. Applications will be reviewed on a rolling basis. Any application received by 15 September 2017 will be considered.
Start dates are flexible.